ArticleScientific reports2025
DFT investigation of therapeutic potential of benzimidazolone capsule as a drug delivery vehicle for anticancer drug.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Computational exploration of anticancer drug adsorption on a porous organic nanocage: Insights from density functional theory for targeted nanocarrier design.Scientific reports · 2026Article
- Unveiling enhanced HCN sensing: a comparative DFT study on reactivity and sensitivity of X-doped biphenylene nanotubes (X = B, Al, and Ga).Scientific reports · 2026Article
- A density functional theory study of cyclophosphamide and purinethol adsorption on a covalent triazine framework (CTF-2) for drug delivery applications.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Numerous issues with pharmacokinetics and water solubility of current anticancer drugs have hindered the development of chemotherapy, resulting in significant side effects and patient resistance to multiple therapies. Nanomedicine revolutionized cancer treatment by introducing nanocarriers to enhance drug delivery. This study investigates the use of benzimidazolone capsules as nanocarrier for drug delivery of flutamide (FLT) and gemcitabine (GB) (FLT@Cap and GB@Cap). Numerous structural and electrical parameters demonstrate that both drugs interact well with nanocapsules and are easily transported to the targeted site. Using complexation energy analysis, quantum theory of atoms in molecules (QTAIM), non-covalent interactions (NCI), natural bond orbital (NBO), frontier molecular orbital (FMO), and density of states (DOS) analyses, the drug delivery of flutamide (FLT) and gemcitabine (GB) via benzimidazolone capsule is described. FLT@Cap and GB@Cap exhibit strong drug-capsule interaction, with adsorption energies of -42.18 and - 51.59 kcal/mol, respectively. QTAIM and NCI analysis validate the non-covalent interactions between FLT, GB, and capsule. To comprehend the shifting of electron density from drug to surface, NBO analysis is utilized. After complexation, (E
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.